Biologics — beyond the joints

详细信息    查看全文

• 作者：Zolt&#xe1 ; n Szekanecz ; S&#xe1 ; ndor Sz&#xe1 ; ntó ; Zolt&#xe1 ; n Szabó ; Andrea V&#xe1 ; ncsa ; Szilvia Szamosi ; Nó ; ra Bodn&#xe1 ; r ; Gabriella Szü ; cs
• 关键词：Biologics ; Rheumatoid arthritis ; Ankylosing spondylitis ; Inflammatory bowel disease ; Psoriasis ; Uveitis ; Atherosclerosis ; Cardiovascular disease
• 刊名：Autoimmunity Reviews
• 出版年：2010
• 出版时间：October 2010
• 年：2010
• 卷：9
• 期：12
• 页码：820-824
• 全文大小：199 K

文摘

Biologics including tumor necrosis factor α (TNF-α), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.